Update date
30 Jun 2021
Shareable Research Card
This metric view shows QNRX - Quoin Pharmaceuticals, Ltd. current assets history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest reported current assets: $3,023,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Update date
30 Jun 2021
Page type
Metric history
Latest period
Q2 2021
SEC-backed company facts were refreshed from filings filed on 07 May 2026.
Benchmark Context
Quoin Pharmaceuticals, Ltd. sits in the bottom quarter of the current current assets sample.
Compared with
Compared with 39 companies reporting current assets in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.1x the current sample midpoint. Current Assets does not yet have enough prior-period data for a historical comparison on this page.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Latest period: Q2 2021. Period end: 30 Jun 2021. Units: USD and ILS. Frequency: quarterly.
Current Assets is reported in company XBRL facts filed with the SEC.
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare latest available Current Assets levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Quoin Pharmaceuticals, Ltd. appears at rank #35 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | CRH PUBLIC LTD CO (crh) | $14,801,000,000 | Instant - 31 Dec 2022 | Open CRH PUBLIC LTD CO Current Assets |
| 2 | CELESTICA INC (cls) | $4,512,600,000 | Instant - 31 Dec 2023 | Open CELESTICA INC Current Assets |
| 3 | SSR MINING INC. (ssrm) | $1,424,522,000 | Instant - 31 Dec 2020 | Open SSR MINING INC. Current Assets |
| 4 | Indivior Pharmaceuticals, Inc. (indv) | $1,263,000,000 | Instant - 31 Dec 2023 | Open Indivior Pharmaceuticals, Inc. Current Assets |
| 5 | Flutter Entertainment plc (flut) | $977,639,000 | Instant - 31 Dec 2019 | Open Flutter Entertainment plc Current Assets |
| 6 | Curaleaf Holdings, Inc. (curlf) | $942,616,000 | Instant - 31 Dec 2021 | Open Curaleaf Holdings, Inc. Current Assets |
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q2 2021 | $3,023,000 | 30 Jun 2021 | 6-K | 24 Aug 2021 | 2021 | Q2 | ||
| Q4 2020 | $5,365,000 | -$10,000 | -0.19% | 31 Dec 2020 | 20-F | 29 Mar 2021 | 2020 | FY |
| Q4 2019 | $5,375,000 | 31 Dec 2019 | 20-F | 03 Apr 2020 | 2019 | FY | ||
| Q2 2018 | $8,467,000 | 30 Jun 2018 | 6-K | 09 Aug 2018 | 2018 | Q2 | ||
| Q4 2017 | $8,235,000 | 31 Dec 2017 | 20-F | 19 Mar 2018 | 2017 | FY |
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q2 2021 | ₪9,855,000 | -₪15,374,000 | -61% | 30 Jun 2021 | 6-K | 24 Aug 2021 | 2021 | Q2 |
| Q4 2020 | ₪17,248,000 | -₪1,327,000 | -7.1% | 31 Dec 2020 | 6-K | 24 Aug 2021 | 2021 | Q2 |
| Q2 2020 | ₪25,229,000 | -₪2,705,000 | -9.7% | 30 Jun 2020 | 6-K/A | 11 Feb 2021 | 2020 | Q2 |
| Q4 2019 | ₪18,575,000 | -₪50,000 | -0.27% | 31 Dec 2019 | 20-F | 29 Mar 2021 | 2020 | FY |
| Q2 2019 | ₪27,934,000 | -₪2,972,000 | -9.6% | 30 Jun 2019 | 6-K | 13 Aug 2019 | 2019 | Q2 |
| Q4 2018 | ₪18,625,000 | -₪9,926,000 | -35% | 31 Dec 2018 | 20-F | 03 Apr 2020 | 2019 | FY |
| Q2 2018 | ₪30,906,000 | 30 Jun 2018 | 6-K | 09 Aug 2018 | 2018 | Q2 | ||
| Q4 2017 | ₪28,551,000 | -₪3,846,000 | -12% | 31 Dec 2017 | 20-F | 18 Mar 2019 | 2018 | FY |
| Q4 2016 | ₪32,397,000 | 31 Dec 2016 | 20-F | 19 Mar 2018 | 2017 | FY |